Scinai

24/02/2026

In Case You Missed It - A Major Step Forward for Scinai!

Last week, we announced a transformative agreement with Recipharm - and it marks an exciting new chapter for Scinai.

The transaction brings together infrastructure, capital support, and a commercial partnership designed to accelerate our CDMO strategy while strengthening our financial foundation.

In a challenging biotech environment, this deal:
✔️ Adds immediate operational capabilities
✔️ Provides meaningful runway
✔️ Aligns us with a global CDMO leader
✔️ Creates a platform for scalable growth

In the video below, Amir shares why this transaction is such a powerful move for Scinai right now - and what it unlocks for the future.

Don’t miss it.

19/02/2026

𝐖𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐞𝐜𝐢𝐩𝐡𝐚𝐫𝐦 𝐈𝐬𝐫𝐚𝐞𝐥 𝐓𝐞𝐚𝐦 𝐭𝐨 𝐭𝐡𝐞 𝐒𝐜𝐢𝐧𝐚𝐢 𝐅𝐚𝐦𝐢𝐥𝐲
Today, our leadership visited Recipharm Israel to personally welcome the new team members into the Scinai family.
We spoke about the integration process between our two companies and the exciting opportunities it brings, as well as the challenges that naturally arise along the way.
We walked away from the meeting energized, aligned, and more focused than ever on our shared mission. With a united vision and a motivated team, the path ahead is full of promise.
A big welcome to the team - looking forward to building our future together.

17/02/2026

: We have officially announced the completion of our of Recipharm Israel Ltd. and strategic commercial collaboration with Recipharm. This milestone marks a tremendously important step forward for Scinai’s manufacturing footprint, capabilities, and commercial positioning, strengthening our CDMO platform and creating a differentiated, end-to-end development and manufacturing offering spanning early development directly by Scinai and late-stage clinical and commercial supply by Recipharm.

Read more: https://www.scinai.com/press-releases/scinai-announces-completion-of-acquisition-of-recipharm-israel-ltd-and-strategic-commercial-collaboration-with-recipharm

05/02/2026

We believe that fostering curiosity starts with real-world exposure. This week, we were excited to host high school students for Apprentice Day at Scinai, where they toured our production facility, attended our business review meetings, and heard insights from our CEO, Amir Reichman, on thoughtful decision-making. Through these experiences, they saw how science, technology, and teamwork drive our daily work.

This visit reflects our commitment to strengthening community ties and encouraging the next generation to explore, question, and lead. We’re grateful for the chance to inspire young minds and to share the passion that drives our mission forward.

שמחנו לארח השבוע תלמידי תיכון מבית ספר ליד האוניברסיטה בירושלים, כחלק מהפעילות שלנו לחיזוק קשרי קהילה וקידום מדעני העתיד.

30/01/2026

Highlighting the below piece by our CEO, Amir Reichman, where he offers his perspective and insights on the VHH antibody space and that while these antibodies are not a "new technology", what matters more than ever in the current environment is the differentiation, clinical context, and ex*****on discipline required within development.

It is clear there is a renewed interest in this modality, and we at Scinai are excited to be at the forefront of innovation!

Bloomberg recently highlighted how large pharmaceutical companies such as Sanofi, AstraZeneca, and Eli Lilly are increasingly investing in nanobody-based biologics in an article titled “Llamas Are Big Pharma’s Secret Weapon to Find New Drugs” by Lisa Pham (January 23, 2026). The article descri...

17/12/2025

ICYMI: Scinai reported our Q3 earnings report last week!

📈 Revenue more than doubled year-over-year, driven by continued growth in our CDMO business and early traction in the U.S. market.
🏭 Non-dilutive funding secured to expand our fill-and-finish manufacturing capabilities, with commercial operations expected in 2026.
🧬 Disciplined R&D ex*****on, with focus on advancing our differentiated NanoAbs pipeline and pursuing significant EU STEP grant opportunities.
💼 Strengthened balance sheet, reflecting careful capital stewardship as we position the company for upcoming milestones.

As we head into 2026, Scinai is focused on scaling its CDMO platform, advancing pipeline programs toward key inflection points, and creating long-term shareholder value!

🔗 Link to the full earnings release in the comments section!

04/12/2025

Scinai CEO, Amir Reichman , is proud to represent Scinai Immunotherapeutics this week as part of the Rhineland-Palatinate Biotech Delegation in Germany!

The delegation is meeting leading institutions - including the Biotechnology Campus Mainz, BioVation RLP, biomindz – Life Science Hub Mainz, UniMed Mainz, Midas Pharma , and Boehringer Ingelheim - to deepen collaboration between Israel and one of Europe’s most vibrant life-science regions.

Amir is highlighting Scinai’s work developing novel I&I biologics and expanding our boutique CDMO capabilities, while connecting with partners across the German innovation ecosystem.

This is a great opportunity to strengthen ties, explore new partnerships, and showcase the impact of Scinai’s science and services!

02/12/2025

Scinai Q3 Earnings — Momentum Building Continues

We are pleased to share the latest results from Scinai: our CDMO business is gaining real traction, and we’ve made meaningful progress on strengthening our financial footing and I&I pipeline!

Key highlights:

📈 CDMO revenue growth continues to outpace expectations, reflecting increasing demand for our biologics manufacturing and development services.

💡 We’re executing on our dual–engine strategy: scaling CDMO services while advancing our proprietary R&D pipeline of nanoAbs for inflammation & immunology (I&I).

👇 On the balance-sheet and cash-flow side: we significantly improved liquidity, reduced net loss compared to prior period, and further de-risked operations via strategic funding.

✅ Taken together — these results underscore that Scinai is no longer just a biotech in waiting. We are executing on a sustainable, dual-track model that combines external-facing manufacturing services with internally developed therapeutics.

Thank you to all colleagues, partners, and investors for the continued trust. We look forward to what’s ahead in the next phase of growth!

(Link to PR in the comments)

16/11/2025

🚀 𝐖𝐞’𝐫𝐞 𝐥𝐢𝐯𝐞! 𝐒𝐜𝐢𝐧𝐚𝐢’𝐬 𝐮𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐢𝐬 𝐨𝐟𝐟𝐢𝐜𝐢𝐚𝐥𝐥𝐲 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝.

At Scinai, we aim to elevate drug development every step of the way, and we invite you to be part of our journey.

Take a deep dive into our exciting I&I pipeline, explore Scinai CDMO BioServices, and gain a glimpse into our 1,850 sqm cGMP facility and state-of-the-art labs. Discover client stories, information resources, and expert insights.

Our upgraded site brings it all together to give biotech innovators a clearer, smarter path forward.

👉 Explore the upgraded website: www.scinai.com

10/11/2025

Industry Insight: Why “Good Data” Sometimes Isn’t Good Enough

Recent Phase 3 readouts in the inflammation and immunology (I&I) space have shown that even statistically positive results may not be enough. Investors and prescribers are increasingly demanding meaningful differentiation: new therapies must not only work but deliver real-world value for patients, physicians, and payers.

At Scinai Immunotherapeutics, we’re addressing this challenge with a first-in-class intradermal nanobody platform designed to deliver biologics locally, directly to the site of inflammation, rather than systemically throughout the body.

Our lead psoriasis program targets patients underserved by current options, including:

Mild-to-moderate patients who wish to avoid chronic topical corticosteroid use due to side effects such as skin atrophy.
Patients using advanced topicals (e.g., ZorivE™, Vtama®) who struggle with daily application and adherence.
Phototherapy patients who must attend frequent outpatient sessions for weeks at a time.
Patients with lesions in sensitive areas (face, scalp, ge****ls, palms, soles) who may currently receive systemic biologics due to the psychosocial burden of their disease, even though their overall disease severity is limited.

Our intradermal administration is performed using a mesogun, a device already well established in dermatology for applications such as hair restoration and skin rejuvenation. This approach enables precise, virtually painless delivery of nanobody-based biologics directly into the affected skin.

By providing a localized, safer, and more convenient alternative to systemic biologics, our technology addresses a key unmet need: offering biologic-level efficacy appropriate to the patient’s disease severity while reducing systemic exposure, improving adherence, and lowering overall treatment costs.

As the field seeks innovation that goes beyond incremental efficacy improvements, Scinai’s localized nanobody platform offers a de-risked, differentiated path to redefining care for inflammatory skin diseases.

👉 Learn more at www.scinai.com

20/10/2025

🤝 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐢𝐧𝐠 𝐟𝐨𝐫 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐀 𝐠𝐥𝐢𝐦𝐩𝐬𝐞 𝐢𝐧𝐭𝐨 𝐨𝐮𝐫 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐰𝐢𝐭𝐡 𝐇𝐨𝐩𝐞𝐜 𝐏𝐡𝐚𝐫𝐦𝐚
When Hopec Pharma set out to develop DOR-100, a novel therapy for Non-Muscle Invasive Bladder Cancer (NMIBC), they needed a CDMO partner to turn their concept into a scalable, GMP-ready process.
“𝑊𝑒 𝑤𝑒𝑟𝑒 𝑖𝑛𝑠𝑝𝑖𝑟𝑒𝑑 𝑏𝑦 𝐻𝑜𝑝𝑒𝑐’𝑠 𝑡𝑒𝑐ℎ𝑛𝑜𝑙𝑜𝑔𝑦 𝑎𝑛𝑑 𝑘𝑛𝑒𝑤 𝑤𝑒 ℎ𝑎𝑑 𝑡𝑜 𝑑𝑒𝑠𝑖𝑔𝑛 𝑎 𝑡𝑎𝑖𝑙𝑜𝑟𝑒𝑑 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 - 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑟𝑖𝑔ℎ𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑎𝑛𝑑 𝑡𝑒𝑠𝑡𝑖𝑛𝑔 - 𝑡𝑜 𝑚𝑒𝑒𝑡 𝑠𝑡𝑟𝑖𝑐𝑡 𝐺𝑀𝑃 𝑎𝑛𝑑 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑s,” says Tehila Sonnenfeld Scinai Director of Production.
Scinai Immunotherapeutics Ltd. team partnered closely with Hopec from development through GMP manufacturing, ensuring a seamless, efficient path to first-in-human production.
💬 Estee Rosen, Co-Founder and Chairwoman at Hopec Pharma, shares: “𝑆𝑐𝑖𝑛𝑎𝑖 𝑡𝑜𝑜𝑘 𝑎 ℎ𝑜𝑙𝑖𝑠𝑡𝑖𝑐 𝑎𝑝𝑝𝑟𝑜𝑎𝑐ℎ 𝑡ℎ𝑎𝑡 𝑤𝑒𝑛𝑡 𝑓𝑎𝑟 𝑏𝑒𝑦𝑜𝑛𝑑 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔 — 𝑓𝑟𝑜𝑚 𝑢𝑛𝑑𝑒𝑟𝑠𝑡𝑎𝑛𝑑𝑖𝑛𝑔 𝑜𝑢𝑟 𝑠𝑐𝑖𝑒𝑛𝑐𝑒 𝑡𝑜 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑔 𝑎𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡, 𝑠𝑐𝑎𝑙𝑎𝑏𝑙𝑒, 𝑎𝑛𝑑 𝑐𝑜𝑚𝑚𝑒𝑟𝑐𝑖𝑎𝑙𝑙𝑦 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠. 𝑇ℎ𝑒𝑖𝑟 𝑒𝑥𝑝𝑒𝑟𝑡𝑖𝑠𝑒 𝑎𝑛𝑑 𝑠𝑢𝑝𝑝𝑜𝑟𝑡 𝑎𝑙𝑙𝑜𝑤𝑒𝑑 𝑢𝑠 𝑡𝑜 𝑚𝑜𝑣𝑒 𝑓𝑜𝑟𝑤𝑎𝑟𝑑 𝑞𝑢𝑖𝑐𝑘𝑙𝑦 𝑎𝑛𝑑 𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑡𝑙𝑦.”
💬 Gadi Klarsfeld, Co-Founder and CEO of Hopec Pharma adds:
“𝑆𝑐𝑖𝑛𝑎𝑖 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑠 𝑓𝑎𝑟 𝑏𝑒𝑦𝑜𝑛𝑑 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐶𝐷𝑀𝑂 𝑠𝑒𝑟𝑣𝑖𝑐𝑒 — ℎ𝑒𝑙𝑝𝑖𝑛𝑔 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑜𝑟𝑠 𝑙𝑖𝑘𝑒 𝑢𝑠 𝑏𝑟𝑖𝑛𝑔 𝑛𝑒𝑤 𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑒𝑠 𝑐𝑙𝑜𝑠𝑒𝑟 𝑡𝑜 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠.”
🎥 Get a glimpse into our project in the video below, and follow the link to view the full video to learn more about Hopec Pharma’s innovative therapy and the journey with Scinai.
Thank you, Estee, Gadi, and the entire Hopec Pharma team, for choosing Scinai as your CDMO partner. We are inspired to collaborate with innovators like you to bring your life-changing therapy to patients.

16/10/2025

אנחנו ב Scinai גאים ונרגשים על הזכייה במסלול מעבדות מו"פ ומאגרי מידע של קרן תשתיות ברשות החדשנות
תודה גדולה לרשות החדשנות על האמון, הליווי והתמיכה המתמשכת – בעלי תרומה משמעותית לקידום הביוטק הישראלי ולחיזוק התעשייה המקומית. 🇮🇱✨

Send a message to learn more